摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2,2-dimethyl-4-oxopentanenitrile | 33235-13-1

中文名称
——
中文别名
——
英文名称
2,2-dimethyl-4-oxopentanenitrile
英文别名
4-Cyano-4-methyl-2-pentanon;2-Methyl-4-oxopentan-2-carbonitril
2,2-dimethyl-4-oxopentanenitrile化学式
CAS
33235-13-1
化学式
C7H11NO
mdl
——
分子量
125.17
InChiKey
XHJHGJBVGBKYJD-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    70 °C(Press: 0.01 Torr)
  • 密度:
    0.929±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.5
  • 重原子数:
    9
  • 可旋转键数:
    2
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.71
  • 拓扑面积:
    40.9
  • 氢给体数:
    0
  • 氢受体数:
    2

SDS

SDS:1efdd0865b11f19265abea21380f012a
查看

反应信息

点击查看最新优质反应信息

文献信息

  • Pyrazolopyridines and analogs thereof
    申请人:Hays S. David
    公开号:US20060100229A1
    公开(公告)日:2006-05-11
    Pyrazolopyridin-4-amines, pyrazoloquinolin-4-amines, pyrazolonaphthyridin-4-amines, and 6,7,8,9-tetrahydropyrazoloquinolin-4-amines, pharmaceutical compositions containing the compounds, intermediates, methods of making, and methods of use of these compounds as immunomodulators, for inducing or inhibiting cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed.
    吡唑吡啶-4-胺,吡唑喹啉-4-胺,吡唑萘啉-4-胺和6,7,8,9-四氢吡唑喹啉-4-胺,含有这些化合物的药物组合物,中间体,制备方法以及将这些化合物用作免疫调节剂的方法,用于诱导或抑制动物体内细胞因子生物合成,并用于治疗包括病毒性和肿瘤性疾病在内的疾病。
  • Substituted Azaspiro(4.5)Decane Derivatives
    申请人:Gruenenthal GmbH
    公开号:US20160016903A1
    公开(公告)日:2016-01-21
    The invention relates to substituted spirocyclic cyclohexane derivatives which have an affinity for the μ opioid receptor and the ORL1 receptor, processes for the preparation thereof, medicaments containing these compounds and the use of these compounds for the preparation of medicaments.
    这项发明涉及对取代的螺环烷环己烷衍生物,其具有对μ阿片受体和ORL1受体的亲和力,以及其制备方法、含有这些化合物的药物和利用这些化合物制备药物的用途。
  • PYRAZOLOPYRIDINES AND ANALOGS THEREOF
    申请人:Hays David S.
    公开号:US20090318435A1
    公开(公告)日:2009-12-24
    Pyrazolopyridin-4-amines, pyrazoloquinolin-4-amines, pyrazolonaphthyridin-4-amines, and 6,7,8,9-tetrahydropyrazoloquinolin-4-amines, pharmaceutical compositions containing the compounds, intermediates, methods of making, and methods of use of these compounds as immunomodulators, for inducing or inhibiting cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed.
    本文介绍了吡唑吡啶-4-胺,吡唑喹啉-4-胺,吡唑萘啉-4-胺和6,7,8,9-四氢吡唑喹啉-4-胺,含有这些化合物的药物组合物,中间体,制备方法以及这些化合物作为免疫调节剂的用途,用于诱导或抑制动物细胞因子生物合成,以及用于治疗包括病毒和肿瘤疾病在内的疾病。
  • Pyrazolopyridines and Analogs Thereof
    申请人:Hays David S.
    公开号:US20090075980A1
    公开(公告)日:2009-03-19
    Pyrazolopyridin-4-amines, pyrazoloquinolin-4-amines, pyrazolonaphthyridin-4-amines, 6,7,8,9-tetrahydropyrazoloquinolin-4-amines, and prodrugs thereof, pharmaceutical compositions containing the compounds, intermediates, methods of making, and methods of use of these compounds as immunomodulators, for inducing or inhibiting cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed.
    本文披露了吡唑吡啶-4-胺、吡唑喹啉-4-胺、吡唑萘啉-4-胺、6,7,8,9-四氢吡唑喹啉-4-胺及其前药、含有这些化合物的制药组合物、中间体、制备方法以及这些化合物作为免疫调节剂的使用方法,包括在动物中诱导或抑制细胞因子生物合成以及治疗病毒和肿瘤性疾病。
  • Reductive amination of carbonylnitriles and similar compounds
    申请人:UNION CARBIDE CHEMICALS AND PLASTICS COMPANY, INC.
    公开号:EP0394967A1
    公开(公告)日:1990-10-31
    Carbonylnitriles and iminonitriles are subjected to reductive amination in two steps, the first of which is at a temperature sufficient to produce the aminonitrile and the second of which is at a higher temperature and/or uses hydrogenation catalyst more reactive toward nitrile groups sufficient to produce the hydrogenated compound. The processes may be conducted under lower pressures, e.g., under about 700 psig, while maintaining desirable selectivity to the aminated product.
    羰基腈和亚氨基腈分两步进行还原胺化,第一步的温度足以生产氨基腈,第二步的温度更高,和/或使用对腈基反应更强的氢化催化剂,足以生产氢化化合物。这些过程可以在较低的压力下进行,例如在约 700 psig 的压力下,同时保持对胺化产物的理想选择性。
查看更多